Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Evaluating JIA Assessment Instruments: Conclusions (2 of 2)
Current evidence is inadequate to fully understand the validity, reliability, and responsiveness of the clinical outcomes measures that are used in composite assessments of JIA (such as the ACR Pediatric).
An outcome instrument that accurately describes all aspects of JIA—including disease activity, functional status, and quality of life—is needed to improve both comparative effectiveness research and understanding of the overall impact of JIA.
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | assessment | validity | reliability | responsiveness
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.